Adaptive Biotechnologies Raises 2026 MRD Revenue Guidance Following Q3 Profitability
Adaptive Biotechnologies (ADPT) reported a breakthrough third quarter, achieving total company profitability ahead of previous expectations. The company highlighted rapid growth in its Minimal Residual Disease (MRD) segment, which serves as a primary driver for its current financial trajectory. Driven by this momentum, management raised its 2026 MRD revenue guidance to a range of $276 million to $286 million. This projection is supported by a target Average Selling Price (ASP) of $1,700 to $1,800 per unit, signaling strong commercial scaling and pricing power in the diagnostic market.
Tickers: $ADPT